I-Chow Joe Hsu, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
I-Chow Joe Hsu, MD

Associate Professor, Department of Radiation Oncology, UCSF

Phone: (415) 353-9807 (appts, new), 353-9894 (appts, follow-up)
Box 0226, UCSF
San Francisco, CA 94143-0226

View on UCSF Profiles

Cancer Center Membership

Associate Member » Prostate Cancer

Education

University of Florida, Gainesville, FL, BS, 1983-87, Biochemistry
Johns Hopkins School of Med., Baltimore, MD, MD, 1987-91, Medicine
San Bernardino County Med. Ctr., SB, CA, 1991-92, Internship
Columbia-Presbyterian Med. Ctr., NY, NY, 1992-95, Residency


Professional Experience

  • 1995-1997
    Attending Physician, Radiation Oncology, California Endocurietherapy Cancer Center, Oakland CA
  • 1997-1998
    Clinical Assistant Professor, Department of Radiation Oncology, University of California San Francisco
  • 1998-2004
    Assistant Professor of Clinical Radiation Oncology, Department of Radiation Oncology, University of California, San Francisco
  • 2004-present
    Associate Professor of Clinical Radiation Oncology, Department of Radiation Oncology, University of California, San Francisco

Honors & Awards

  • 1987
    Alpha Epsilon Delta Medical Honor Society
  • 1987
    University of Florida, BS, Magna cum Laude
  • 1988, 1990
    Dean's Fund for Research, Johns Hopkins School of Medicine
  • 1989
    The John Scott McFarland Fund, Johns Hopkins School of Medicine
  • 1991
    Accolade for Outstanding Intern, San Bernardino County Hospital

Selected Publications

  1. Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016; 11(1):8.
    View on PubMed
  2. Raleigh DR, Chang AJ, Tomlin B, Cunha JA, Braunstein SE, Shinohara K, Gottschalk AR, Roach M, Hsu IC. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer. Brachytherapy. 2015 Jul 18.
    View on PubMed
  3. Tinkle CL, Weinberg V, Chen LM, Littell R, Cunha JA, Sethi RA, Chan JK, Hsu IC. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes. Int J Radiat Oncol Biol Phys. 2015 Aug 1; 92(5):1093-100.
    View on PubMed
  4. Hsu CC, Paciorek AT, Cooperberg MR, Roach M, Hsu IC, Carroll PR. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov; 116(5):713-20.
    View on PubMed
  5. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, Hsu IC, Gottschalk AR. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-72.
    View on PubMed
  6. Cunha JA, Mellis K, Sethi R, Siauw T, Sudhyadhom A, Garg A, Goldberg K, Hsu IC, Pouliot J. Evaluation of PC-ISO for Customized, 3D Printed, Gynecologic 192-Ir HDR Brachytherapy Applicators. J Appl Clin Med Phys. 2015; 16(1):5168.
    View on PubMed
  7. Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy. Brachytherapy. 2015 Mar-Apr; 14(2):185-8.
    View on PubMed
  8. Gustafson GS, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Hsu IC, Lloyd S, Mclaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1125-30, 1132-6.
    View on PubMed
  9. Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, Myerson R, Stauffer P, Hsu IC, Diederich C, Straube W, Boss MK, Boico A, Craciunescu O, Maccarini P, Needham D, Borys N, Blackwell KL, Dewhirst MW. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014 Aug; 30(5):285-94.
    View on PubMed
  10. Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53.
    View on PubMed
  11. Nguyen PL, Aizer A, Assimos DG, D'Amico AV, Frank SJ, Gottschalk AR, Gustafson GS, Hsu IC, McLaughlin PW, Merrick G, Rosenthal SA, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
    View on PubMed
  12. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. Response to Drs Rogers, Hayes, and Demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5.
    View on PubMed
  13. Chen CP, Braunstein S, Mourad M, Hsu IC, Haas-Kogan D, Roach M, Fogh SE. Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: Single-institution prospective study at University of California, San Francisco. Pract Radiat Oncol. 2015 Jan-Feb; 5(1):e45-51.
    View on PubMed
  14. Salgaonkar VA, Prakash P, Rieke V, Ozhinsky E, Plata J, Kurhanewicz J, Hsu IC, Diederich CJ. Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MR-guided endorectal HIFU ablation array. Med Phys. 2014 Mar; 41(3):033301.
    View on PubMed
  15. Nattagh K, Siauw T, Pouliot J, Hsu IC, Cunha JA. A training phantom for ultrasound-guided needle insertion and suturing. Brachytherapy. 2014 Jul-Aug; 13(4):413-9.
    View on PubMed
  16. Thomadsen BR, Erickson BA, Eifel PJ, Hsu IC, Patel RR, Petereit DG, Fraass BA, Rivard MJ. A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy: executive summary. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):65-70.
    View on PubMed
  17. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9:42.
    View on PubMed
  18. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M. Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol. 2014 Jan 16.
    View on PubMed
  19. Hsu IC, Hunt D, Straube, W, Pouliot J, Cunha A, Krishnamurthy D, Sandler H. Dosimetric Analysis of Radiation Therapy Oncology Group 0321: The Importance of Urethral Dose. Practical Radiation Oncology. 2014; 4:27-34.
    View on PubMed
  20. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.
    View on PubMed

Go to UCSF Profiles, powered by CTSI